Abstract
Background: Drug screening is rapid, inexpensive, and is often used in clinical, forensic, and workplace drug testing to gain informative results. This article seeks to determine if bupropion and/or its metabolites is resulting in false-positive amphetamine screening results in our case samples using commercially available enzymelinked immunosorbent assay tests. Method: Fortified urine and forensic case samples were used to determine crossreactivity of bupropion and its main metabolite to four different amphetamine and methamphetamine enzyme-linked immunosorbent assay kits. Results: Two of the enzyme-linked immunosorbent assay kits used to screen for amphetamine may result in false-positive results if bupropion metabolites are present in concentrations greater than 500 ng/mL. Three case samples gave a positive screen results for amphetamine using Amphetamine ULTRA kits, yet no amphetamines were confirmed by gas chromatography-mass spectrometry and all samples were positive for bupropion and metabolites. Conclusions: Laboratory directors and clinicians should be aware of the characteristic of their chosen laboratory assay and should communicate this to physicians so that results can be interpreted accurately.
Original language | English (US) |
---|---|
Pages (from-to) | 366-368 |
Number of pages | 3 |
Journal | Therapeutic Drug Monitoring |
Volume | 33 |
Issue number | 3 |
DOIs | |
State | Published - Jun 1 2011 |
Keywords
- Amphetamine
- Bupropion metabolite
- ELISA
- False-positive
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology